ANNA, Konieczna, Vendula NOVÁKOVÁ, Jiřina MEDALOVÁ, Erceg SLAVEN and Martin KLABUSAY. Thiazolidinediones Regulate the Level of ABC Transporters Expression on Lung Cancer Cells. Klinicka onkologie Journal. 2015, vol. 28, No 6, p. 431-438. ISSN 0862-495X. Available from: https://dx.doi.org/10.14735/amko2015431.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Thiazolidinediones Regulate the Level of ABC Transporters Expression on Lung Cancer Cells
Authors ANNA, Konieczna (203 Czech Republic), Vendula NOVÁKOVÁ (203 Czech Republic), Jiřina MEDALOVÁ (203 Czech Republic, belonging to the institution), Erceg SLAVEN (203 Czech Republic) and Martin KLABUSAY (203 Czech Republic, guarantor).
Edition Klinicka onkologie Journal, 2015, 0862-495X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30105 Physiology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14310/15:00086936
Organization unit Faculty of Science
Doi http://dx.doi.org/10.14735/amko2015431
Keywords in English Thiazolidinedion; ABC Transporters; Lung Cancer
Tags AKR
Changed by Changed by: Mgr. Jiřina Medalová, Ph.D., učo 176525. Changed: 13/3/2018 11:11.
Abstract
ATP binding cassette (ABC) transporters related to multidrug resistance (MDR) actively efflux various xenobiotics from the cells across the cell membrane and decrease a drugs efficiency. Lung cancer is the leading cause of death among all types of cancer in the Czech Republic, and its incidence is still rising. Ciglitazone, rosiglitazone and troglitazone belonging to PPARgama agonist family (formerly used in diabetes mellitus treatment) were selected to investigate their capability to influence expression of ABC transporters on lung cancer cells. Therefore, the effect of PPARgama of agonists on transcription of following ABC transporters was investigated: multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein (BCRP). We have investigated if these PPARgama agonists are substrates of ABC transporters using HL60 and HL60 derived cell lines (HL60-MDR1, HL60-MRP1, PLB-BCRP) by cytotoxicity test WST-1. We have mapped the changes in mRNA expression level of those transporters in A549 and HEK293 cells after PPARgama agonists treatment using quantitative reverse transcription real-time PCR (qRT-PCR). All three PPARgama agonists serve as substrates to at least one ABC transporter under study.PPARgama activation correlates with the upregulation of PTEN, which may modulate the expression of ABC transporters via PI3K/Akt signaling pathway. We have shown that rosiglitazone and troglitazone inhibit mRNA expression of MDR1 transporter in both cell lines whereas the expression of MRP1 in HEK293 cell was up-regulated after rosiglitazone treatment and the expression of MDR1 was upregulated after ciglitazone treatment
PrintDisplayed: 22/8/2024 13:10